Presentation

OxThera AB is pioneering a novel microbiome-derived live biotherapeutic products (LBP) for the treatment of ultra orphan diseases, such as Primary Hyperoxaluria (PH). Our lead product Oxabact® OC5 is a highly concentrated freeze-dried live bacteria (Oxalobacter formigenes) delivered in an enterically coated capsule twice daily. We have fully enrolled our Phase 3 ePHex Study in PH and expect to have Topline results by mid 2021.
OxThera’s strategy is to progress Oxabact through clinical development and commercialize the product in Europe and the United States.